FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4221005916> ?p ?o ?g. }

• W4221005916 endingPage "530" @default.
• W4221005916 startingPage "521" @default.
• W4221005916 abstract "BackgroundThe clinical presentation and outcomes of non-alcoholic fatty liver disease (NAFLD)-related hepatocellular carcinoma are unclear when compared with hepatocellular carcinoma due to other causes. We aimed to establish the prevalence, clinical features, surveillance rates, treatment allocation, and outcomes of NAFLD-related hepatocellular carcinoma.MethodsIn this systematic review and meta-analysis, we searched MEDLINE and Embase from inception until Jan 17, 2022, for articles in English that compared clinical features, and outcomes of NAFLD-related hepatocellular carcinoma versus hepatocellular carcinoma due to other causes. We included cross-sectional and longitudinal observational studies and excluded paediatric studies. Study-level data were extracted from the published reports. The primary outcomes were (1) the proportion of hepatocellular carcinoma secondary to NAFLD, (2) comparison of patient and tumour characteristics of NAFLD-related hepatocellular carcinoma versus other causes, and (3) comparison of surveillance, treatment allocation, and overall and disease-free survival outcomes of NAFLD-related versus non-NAFLD-related hepatocellular carcinoma. We analysed proportional data using a generalised linear mixed model. Pairwise meta-analysis was done to obtain odds ratio (OR) or mean difference, comparing NAFLD-related with non-NAFLD-related hepatocellular carcinoma. We evaluated survival outcomes using pooled analysis of hazard ratios.FindingsOf 3631 records identified, 61 studies (done between January, 1980, and May, 2021; 94 636 patients) met inclusion criteria. Overall, the proportion of hepatocellular carcinoma cases secondary to NAFLD was 15·1% (95% CI 11·9–18·9). Patients with NAFLD-related hepatocellular carcinoma were older (p<0·0001), had higher BMI (p<0·0001), and were more likely to present with metabolic comorbidities (diabetes [p<0·0001], hypertension [p<0·0001], and hyperlipidaemia [p<0·0001]) or cardiovascular disease at presentation (p=0·0055) than patients with hepatocellular carcinoma due to other causes. They were also more likely to be non-cirrhotic (38·5%, 27·9–50·2 vs 14·6%, 8·7–23·4 for hepatocellular carcinoma due to other causes; p<0·0001). Patients with NAFLD-related hepatocellular carcinoma had larger tumour diameters (p=0·0087), were more likely to have uninodular lesions (p=0·0003), and had similar odds of Barcelona Clinic Liver Cancer stages, TNM stages, alpha fetoprotein concentration, and Eastern Cooperative Oncology Group (ECOG) performance status to patients with non-NAFLD-related hepatocellular carcinoma. A lower proportion of patients with NAFLD-related hepatocellular carcinoma underwent surveillance (32·8%, 12·0–63·7) than did patients with hepatocellular carcinoma due to other causes (55·7%, 24·0–83·3; p<0·0001). There were no significant differences in treatment allocation (curative therapy, palliative therapy, and best supportive care) between patients with NAFLD-related hepatocellular carcinoma and those with hepatocellular carcinoma due to other causes. Overall survival did not differ between the two groups (hazard ratio 1·05, 95% CI 0·92–1·20, p=0·43), but disease-free survival was longer for patients with NAFLD-related hepatocellular carcinoma (0·79, 0·63–0·99; p=0·044). There was substantial heterogeneity in most analyses (I2>75%), and all articles had low-to-moderate risk of bias.InterpretationNAFLD-related hepatocellular carcinoma is associated with a higher proportion of patients without cirrhosis and lower surveillance rates than hepatocellular carcinoma due to other causes. Surveillance strategies should be developed for patients with NAFLD without cirrhosis who are at high risk of developing hepatocellular carcinoma.FundingNone." @default.
• W4221005916 created "2022-04-03" @default.
• W4221005916 creator A5002505234 @default.
• W4221005916 creator A5003334120 @default.
• W4221005916 creator A5004639766 @default.
• W4221005916 creator A5009193858 @default.
• W4221005916 creator A5015041967 @default.
• W4221005916 creator A5025459684 @default.
• W4221005916 creator A5026911776 @default.
• W4221005916 creator A5028905834 @default.
• W4221005916 creator A5033842737 @default.
• W4221005916 creator A5040791928 @default.
• W4221005916 creator A5044089244 @default.
• W4221005916 creator A5052059601 @default.
• W4221005916 creator A5058087480 @default.
• W4221005916 creator A5065179897 @default.
• W4221005916 creator A5065450421 @default.
• W4221005916 creator A5070639714 @default.
• W4221005916 creator A5074144199 @default.
• W4221005916 creator A5077629563 @default.
• W4221005916 date "2022-04-01" @default.
• W4221005916 modified "2023-10-17" @default.
• W4221005916 title "Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis" @default.
• W4221005916 cites W1530466595 @default.
• W4221005916 cites W1776128289 @default.
• W4221005916 cites W1967365717 @default.
• W4221005916 cites W1982967337 @default.
• W4221005916 cites W2022514002 @default.
• W4221005916 cites W2025095846 @default.
• W4221005916 cites W2039418122 @default.
• W4221005916 cites W2045479938 @default.
• W4221005916 cites W2076341209 @default.
• W4221005916 cites W2107328434 @default.
• W4221005916 cites W2117454090 @default.
• W4221005916 cites W2137591261 @default.
• W4221005916 cites W2157823046 @default.
• W4221005916 cites W2167191881 @default.
• W4221005916 cites W2170892587 @default.
• W4221005916 cites W2180006680 @default.
• W4221005916 cites W2277004004 @default.
• W4221005916 cites W2303816016 @default.
• W4221005916 cites W2319677873 @default.
• W4221005916 cites W2525599958 @default.
• W4221005916 cites W2582878252 @default.
• W4221005916 cites W2744982526 @default.
• W4221005916 cites W2806839461 @default.
• W4221005916 cites W2808368206 @default.
• W4221005916 cites W2886443073 @default.
• W4221005916 cites W2886906900 @default.
• W4221005916 cites W2891690058 @default.
• W4221005916 cites W2924630617 @default.
• W4221005916 cites W2930850699 @default.
• W4221005916 cites W2969802526 @default.
• W4221005916 cites W2980176227 @default.
• W4221005916 cites W2983020673 @default.
• W4221005916 cites W3004467589 @default.
• W4221005916 cites W3009311769 @default.
• W4221005916 cites W3020371609 @default.
• W4221005916 cites W3036645444 @default.
• W4221005916 cites W3081063180 @default.
• W4221005916 cites W3110693913 @default.
• W4221005916 cites W3117083078 @default.
• W4221005916 cites W3118615836 @default.
• W4221005916 cites W3128646645 @default.
• W4221005916 cites W3131175249 @default.
• W4221005916 cites W3159857277 @default.
• W4221005916 cites W3160163020 @default.
• W4221005916 cites W3186183728 @default.
• W4221005916 cites W3197152509 @default.
• W4221005916 cites W3204858673 @default.
• W4221005916 cites W3214518912 @default.
• W4221005916 cites W4200279068 @default.
• W4221005916 cites W4206004696 @default.
• W4221005916 cites W4206634604 @default.
• W4221005916 cites W4210774372 @default.
• W4221005916 cites W4214491746 @default.
• W4221005916 doi "https://doi.org/10.1016/s1470-2045(22)00078-x" @default.
• W4221005916 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35255263" @default.
• W4221005916 hasPublicationYear "2022" @default.
• W4221005916 type Work @default.
• W4221005916 citedByCount "91" @default.
• W4221005916 countsByYear W42210059162022 @default.
• W4221005916 countsByYear W42210059162023 @default.
• W4221005916 crossrefType "journal-article" @default.
• W4221005916 hasAuthorship W4221005916A5002505234 @default.
• W4221005916 hasAuthorship W4221005916A5003334120 @default.
• W4221005916 hasAuthorship W4221005916A5004639766 @default.
• W4221005916 hasAuthorship W4221005916A5009193858 @default.
• W4221005916 hasAuthorship W4221005916A5015041967 @default.
• W4221005916 hasAuthorship W4221005916A5025459684 @default.
• W4221005916 hasAuthorship W4221005916A5026911776 @default.
• W4221005916 hasAuthorship W4221005916A5028905834 @default.
• W4221005916 hasAuthorship W4221005916A5033842737 @default.
• W4221005916 hasAuthorship W4221005916A5040791928 @default.
• W4221005916 hasAuthorship W4221005916A5044089244 @default.
• W4221005916 hasAuthorship W4221005916A5052059601 @default.
• W4221005916 hasAuthorship W4221005916A5058087480 @default.
• W4221005916 hasAuthorship W4221005916A5065179897 @default.

• next